Drugs / DLX105-DMP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04203433 | Mar → Sep 2022 | psoriasis | DelArrivo, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLX105-DMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04203433 ↗ |
| Route | Topical | “1mg applied to target lesion” NCT04203433 ↗ |